Spesolimab-Sbzo

How is Spesolimab-Sbzo dosed?

Dosage information is not provided. Please consult a healthcare professional for proper dosage instructions.

What is the dosage form of Spesolimab-Sbzo?

Spesolimab-Sbzo is administered intravenously in the form of a solution.

What medications are contraindication with Spesolimab-Sbzo?

Serious skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), can occur with Spesolimab-Sbzo. It is advised to avoid immunizations (vaccines) without doctor's approval while using Spesolimab-Sbzo. Consult a healthcare professional for guidance on potential drug interactions or contraindications.

How is Spesolimab-Sbzo administered?

Spesolimab-Sbzo is administered by a healthcare professional in a medical facility through a needle placed into a vein. The medicine is slowly administered over at least 90 minutes. It is important to carefully follow the instructions provided in the Medication Guide.

What are common precautions when taking Spesolimab-Sbzo?

Common precautions when taking Spesolimab-Sbzo intravenous route include:

  1. Allergic reactions: Inform your doctor about any allergies to medications, foods, dyes, preservatives, or animals.
  2. Pregnancy and breastfeeding: Limited information is available on the safety of Spesolimab-Sbzo during pregnancy and breastfeeding. Consult your doctor before taking the medication in these situations.
  3. Skin reactions: Spesolimab-Sbzo can cause serious skin reactions, including DRESS. Inform your doctor immediately if you experience any unusual skin reactions such as rash, itching, or swelling.
  4. Immunization: Avoid receiving live virus vaccines while being treated with Spesolimab-Sbzo. Consult your doctor before getting any vaccines.
  5. Kidney function: Spesolimab-Sbzo may affect kidney function. Inform your doctor if you have any kidney issues or if you are receiving dialysis treatment.
  6. Liver function: Spesolimab-Sbzo may affect liver function. Inform your doctor if you have any liver issues.